$Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center$

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center

Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azac...

Full description

Bibliographic Details
Main Authors:	Matthew E. Tenold, Benjamin N. Moskoff, David J. Benjamin, Rasmus T. Hoeg, Aaron S. Rosenberg, Mehrdad Abedi, Joseph M. Tuscano, Brian A. Jonas
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-03-01
Series:	Frontiers in Oncology
Subjects:	acute myeloid leukemia venetoclax (BCL-2 inhibitor) hypomethylating agent relapsed/refractory real-world data
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.649209/full

Similar Items

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
by: Huber H, et al.
Published: (2017-02-01)

Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified
by: Kaiqi Liu, et al.
Published: (2021-09-01)

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting
by: Tong J, et al.
Published: (2021-07-01)

Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
by: Khadega A. Abuelgasim, et al.
Published: (2020-04-01)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
by: Nicola Sgherza, et al.
Published: (2021-09-01)

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
by: Aleksina Shatilova, et al.
Published: (2021-05-01)

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: A case report and review of literature
by: Nosha Farhadfar, et al.
Published: (2021-09-01)

Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
by: Nil Albiol, et al.
Published: (2021-06-01)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
by: Schieber M, et al.
Published: (2019-03-01)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
by: Elisabetta Zappone, et al.
Published: (2020-10-01)

Development of venetoclax for therapy of lymphoid malignancies
by: Zhu H, et al.
Published: (2017-03-01)

Potential Biomarkers for Treatment Response to the BCL-2 Inhibitor Venetoclax: State of the Art and Future Directions
by: Haneen T. Salah, et al.
Published: (2021-06-01)

Review of Venetoclax in CLL, AML and Multiple Myeloma
by: Masa Lasica, et al.
Published: (2021-05-01)

B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma
by: Amber Loren O. King, BA, et al.
Published: (2021-02-01)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
by: Joel D. Leverson, et al.
Published: (2018-10-01)

Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report
by: Xuzhao Zhang, et al.
Published: (2021-07-01)

IDH1-mutated relapsed or refractory AML: current challenges and future prospects
by: Megías-Vericat JE, et al.
Published: (2019-06-01)

Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience
by: Matteo Piccini, et al.
Published: (2021-04-01)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
by: Bachar Samra, et al.
Published: (2020-11-01)

Hypomethylating Agents (HMAs) as Salvage Therapy in Relapsed or Refractory AML: An Italian Multicentric Retrospective Study
by: Federica Lessi, et al.
Published: (2021-08-01)

A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia
by: Yuhang Li, et al.
Published: (2021-08-01)

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
by: Delin Yuan, et al.
Published: (2021-03-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Association between long interspersed nuclear element-1 methylation levels and relapse in Wilms tumors
by: Bruna M. de Sá Pereira, et al.
Published: (2017-12-01)

225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models
by: Ravendra Garg, et al.
Published: (2021-02-01)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
by: Rie Nishi, et al.
Published: (2020-10-01)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
by: Stefanie Jilg, et al.
Published: (2019-04-01)

Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
by: Stefano Molica, et al.
Published: (2021-06-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia
by: Valerio Guarente, et al.
Published: (2021-09-01)

Venetoclax: evidence to date and clinical potential
by: Luis Miguel Juárez-Salcedo, et al.
Published: (2019-10-01)

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (literature review)
by: T. E. Byalik
Published: (2018-07-01)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
by: Knight T, et al.
Published: (2019-04-01)

Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients
by: Ferrarini, I., et al.
Published: (2022)

Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
by: Li L, et al.
Published: (2018-10-01)

BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells
by: Alhoshani A, et al.
Published: (2020-12-01)

On the Stability and Degradation Pathways of Venetoclax under Stress Conditions
by: Nina Žigart, et al.
Published: (2020-07-01)

Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials
by: Qingfang Li, et al.
Published: (2019-06-01)

Treatment of Relapsed and Refractory Hodgkin’s Lymphoma in Children
by: NS Kulichkina, et al.
Published: (2016-01-01)